Mixed surfactant modified graphene oxide nanocarriers for DOX delivery to cisplatin-resistant human ovarian carcinoma cells

Zhang, Qian; Chi, Huirong; Tang, Mingzhi; Chen, Jiabin; Li, Guolin; Liu, Yushi; Liu, Bing

doi:10.1039/c6ra17609g

Cited by 16 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was shown by the high reversal index value, expressed as the ratio between IC 50 values of free DOX and DOX@GO. Similar results were obtained by a self-assembled G−dextran nanohybrid, fabricated by π−π interactions of GO and hematin-terminated dextran (HDex) [154], or a GO nanocarrier prepared by using hydroxyethyl cellulose (HEC) and polyanionic cellulose (PAC) as nonionic-anionic synergistic surfactants for GO stabilization in serum [155].…”

Section: Pristine and Non-covalently Functionalized Cnsupporting

confidence: 66%

Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

Carbon nanostructures (CN) are emerging valuable materials for the assembly of highly engineered multifunctional nanovehicles for cancer therapy, in particular for counteracting the insurgence of multi-drug resistance (MDR). In this regard, carbon nanotubes (CNT), graphene oxide (GO), and fullerenes (F) have been proposed as promising materials due to their superior physical, chemical, and biological features. The possibility to easily modify their surface, conferring tailored properties, allows different CN derivatives to be synthesized. Although many studies have explored this topic, a comprehensive review evaluating the beneficial use of functionalized CNT vs G or F is still missing. Within this paper, the most relevant examples of CN-based nanosystems proposed for MDR reversal are reviewed, taking into consideration the functionalization routes, as well as the biological mechanisms involved and the possible toxicity concerns. The main aim is to understand which functional CN represents the most promising strategy to be further investigated for overcoming MDR in cancer.

show abstract

Section: Pristine and Non-covalently Functionalized Cnsupporting

confidence: 66%

Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Compared with the previous studies, it is a very familiar method to deliver chemotherapy drugs (DOX) into tumor cells. 55 However, multidrug resistance is an important factor which should be regarded, and the toxicity of DOX also cannot be ignored. Functionalized GO as a nonviral carrier for siRNA delivery has been explored in previous research.…”

Section: Resultsmentioning

confidence: 99%

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Sun¹,

Wang²,

Cui³

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundGraphene oxide (GO) has attracted intensive interest in biological and medical fields in recent years due to its unique physical, chemical, and biological properties. In our previous work, we proved that GO could deliver small interfering RNA (siRNA) into cells and downregulate the expression of the desired gene.MethodsThis study investigated the potential of a modified GO nanocarrier for co-delivery of siRNA and doxorubicin (DOX) for enhanced cancer therapy. Fourier transform infrared spectroscopy, laser particle size analyzer, UV-visible spectroscopy, gel electrophoresis retardation, and in vitro release assay were studied.ResultsThe results of real-time polymerase chain reaction revealed that the expression of vascular endothelial growth factor (VEGF) mRNA was decreased 46.84%±3.72% (mean ± SD). Enzyme-linked immunosorbent assay indicated that the expression of VEGF protein was down-regulated to 52.86%±1.10% (mean ± SD) in vitro. In vivo tumor growth assay GO-poly-l-lysine hydrobromide/folic acid (GPF)/DOX/siRNA exhibited gene silencing and tumor inhibition (66.95%±2.35%, mean ± SD) compared with naked siRNA (1.62%±1.47%, mean ± SD) and DOX (33.63%±5.85%, mean ± SD). GPF/DOX/siRNA exhibited no testable cytotoxicity.ConclusionThe results indicated that co-delivery of siRNA and DOX by GPF could be a promising application in tumor clinical therapy.

show abstract

“…Table S1 reports the title, first author, journal, date of publication, and DOI for the seventeen publications [44,[64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79]. Those included were published in sixteen scientific journals ranging from 2008 to 2021.…”

Section: Methodsmentioning

confidence: 99%

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

2021

View full text Add to dashboard Cite

Cancer remains one of the leading causes of death worldwide despite extensive efforts at developing curative treatments. Chemotherapy, one of the most common forms of treatment, lacks specificity and can induce collateral damages to healthy surrounding tissues/cells and elicit off-target toxic side effects. The carbon-based nanomaterial graphene, can load aromatic drugs with high efficiency, has good biocompatibility, and can be easily functionalised with targeting ligands, antibodies, and biomolecules to increase the accuracy of targeting specific areas; graphene has therefore been explored as a nanocarrier for classical chemotherapy drugs. In this work, seventeen publications that report the release of doxorubicin (DOX) from 2D graphene-based nanohybrids (graphene oxide and reduced graphene oxide) for the treatment of breast and ovarian cancers have been identified based on a range of inclusion and exclusion criteria. To aid in the clinical translation of proof-of-concept studies, this work identifies the pre-clinical experimental protocols and analyses the release kinetics of these publications. Fifteen of the papers utilised a change in pH as the stimulus for drug release, and two utilised either near infrared (NIR) or ultrasound as the stimulus. The extracted drug release data from these publications were fit to four known kinetic models. It was found that the majority of these data best fit the Weibull kinetic model. The agreement between the kinetic data in previously published literature provides a predictable estimation of DOX release from graphene-based nanocarriers. This study demonstrates the potential conjugation of graphene and DOX in drug delivery applications, and this knowledge can help improve to the design and formulation of future graphene-based nanocarriers. In addition, the use of further experimental testing and the standardisation of experimental protocols will be beneficial for future work. The incorporation of computational modelling prior to pre-clinical testing will also aid in the development of controlled and sustained DOX release systems that offer efficient and efficacious results.

show abstract

Mixed surfactant modified graphene oxide nanocarriers for DOX delivery to cisplatin-resistant human ovarian carcinoma cells

Abstract: Mixed surfactant modified graphene oxide nanocarriers based on the nonideal mixed micelle theory of surfactants exhibit great potential in drug delivery.

Cited by 16 publications

References 47 publications

Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment

Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

Contact Info

Product

Resources

About